Stockreport

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

AIM ImmunoTech Inc.  (AIM) 
PDF OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its fin [Read more]